Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Celestimo : Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaFollicular Lymphoma

Trial Overview Read MoreRead more

This Phase III trial is comparing the effectiveness of two targeted therapies (mosunetuzumab and rituximab) when they are combined with another cancer drug (lenalidomide) in people with follicular lymphoma who have received previous treatment.
 

This trial is treating patients with relapsed or refractory follicular lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Commercial Sponsor

Hoffmann-La Roche

Summary

This is a randomised trial with two experimental arms. The Cycle length for treatment in this trial is: 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12. Participants in Experimental Arm A will receive Mosunetuzumab (administered intravenously in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12) in combination with Lenalidomide (administered orally once daily on Days 1-21 of Cycles 2-12). Participants in Experimental Arm B will receive Rituximab (administered intravenously on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11) in combination with Lenalidomide (administered orally once daily on Days 1-21 of Cycles 1-12). Tociluzumab will be administered as needed to manage cytokine release syndrome (CRS) events.

Recruiting Hospitals Read MoreRead more

Barwon Health, University Hospital Geelong
Geelong
Haematology Team
HaematologyTrials@barwonhealth.org.au

Alfred Hospital, Endocrinology & Diabetes
Prahran
Faeeza Davids
f.davids@alfred.org.au
03 9076 5490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next